Amgen (FRA:AMG) Long-Term Debt: €44,881 Mil (As of Mar. 2026)


FRA:AMG Amgen Inc FRA:AMG
83 GF Score
Price €314.10
GF Value €305.73
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is Amgen Long-Term Debt?

Amgen FRA:AMG -1.51% 83 Long-Term Debt is €44,881 Mil as of Mar. 2026. GuruFocus rates FRA:AMG with a GF Score™ of 83/100 and a GF Value™ of €305.73 (Fairly Valued). The stock has 8 warning signs investors should review.

Amgen's Long-Term Debt for the quarter that ended in Mar. 2026 was €44,881 Mil.

Amgen's quarterly Long-Term Debt declined from Sep. 2025 (€44,674 Mil) to Dec. 2025 (€42,704 Mil) but then increased from Dec. 2025 (€42,704 Mil) to Mar. 2026 (€44,881 Mil).

Amgen's annual Long-Term Debt declined from Dec. 2023 (€57,927 Mil) to Dec. 2024 (€54,004 Mil) and declined from Dec. 2024 (€54,004 Mil) to Dec. 2025 (€42,704 Mil).

Amgen  (FRA:AMG) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Amgen Long-Term Debt Related Terms

Amgen Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Amgen's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amgen Long-Term Debt Chart

Amgen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 29,401.47 35,262.18 57,926.89 54,004.30 42,704.27

Amgen Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 49,962.03 46,609.92 44,673.77 42,704.27 44,881.39
FRA:AMG
83GF Score
Amgen Inc FRA:AMG
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of €44,881 Mil mean?
Amgen (FRA:AMG) has a Long-Term Debt of €44,881 Mil as of Mar. 2026.
Is Amgen's Long-Term Debt too high?
Amgen's current Long-Term Debt is €44,881 Mil. Overall, Amgen has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Amgen's Long-Term Debt compare to GILD and PFE?
Amgen's Long-Term Debt of €44,881 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Amgen's current Long-Term Debt is €44,881 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amgen stock overvalued right now?
Based on GuruFocus' analysis, Amgen (FRA:AMG) is currently considered Fairly Valued. The stock's GF Value™ is €305.73, compared to a current price of €314.10 — trading 2.7% above its estimated fair value. The current Long-Term Debt is €44,881 Mil. Amgen's overall GF Score™ is 83/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Amgen (FRA:AMG), the current Long-Term Debt is €44,881 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amgen (FRA:AMG) Overvalued in 2026?

Based on GuruFocus' analysis, Amgen stock appears to be overvalued. The current stock price of €314.10 is trading 2.7% above its estimated GF Value™ of €305.73. GuruFocus considers Amgen to be Fairly Valued.

Key valuation signals for FRA:AMG:

  • Long-Term Debt: €44,881 Mil
  • GF Value™: €305.73 vs. price of €314.10 (2.7% above fair value)
  • GF Score™: 83/100 with 8 warning signs

No single metric tells the full story. See the FRA:AMG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Amgen Business Description

Address One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
83GF Score

Get the complete analysis for FRA:AMG

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€314.10
Price
€305.73
GF Value